000144635 001__ 144635
000144635 005__ 20240229123019.0
000144635 0247_ $$2doi$$a10.1093/jnci/djz166
000144635 0247_ $$2pmid$$apmid:31435679
000144635 0247_ $$2ISSN$$a0027-8874
000144635 0247_ $$2ISSN$$a0198-0157
000144635 0247_ $$2ISSN$$a1460-2105
000144635 0247_ $$2altmetric$$aaltmetric:65441327
000144635 037__ $$aDKFZ-2019-02077
000144635 041__ $$aeng
000144635 082__ $$a610
000144635 1001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, Tilman$$b0$$eFirst author$$udkfz
000144635 245__ $$aPre-diagnostic plasma bile acid levels and colon cancer risk: A prospective study.
000144635 260__ $$aOxford$$bOxford Univ. Press$$c2020
000144635 3367_ $$2DRIVER$$aarticle
000144635 3367_ $$2DataCite$$aOutput Types/Journal article
000144635 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1601380253_10578
000144635 3367_ $$2BibTeX$$aARTICLE
000144635 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144635 3367_ $$00$$2EndNote$$aJournal Article
000144635 500__ $$a2020 May 1;112(5):516-524#EA:C020#LA:C020#
000144635 520__ $$aBile acids have been proposed to promote colon carcinogenesis. However, there are limited prospective data on circulating bile acid levels and colon cancer risk in humans.Associations between pre-diagnostic plasma levels of 17 primary, secondary and tertiary bile acid metabolites (conjugated and unconjugated) and colon cancer risk were evaluated in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Bile acid levels were quantified by tandem mass spectrometry in samples from 569 incident colon cancer cases and 569 matched controls. Multivariable logistic regression analyses were used to estimate odds ratios (ORs) for colon cancer risk across quartiles of bile acid concentrations.Positive associations were observed between colon cancer risk and plasma levels of 7 conjugated bile acid metabolites, i.e. primary bile acids glycocholic acid (ORQuartile 4 vs. Quartile 1=2.22,95 % confidence interval[CI]=1.52, 3.26), taurocholic acid (OR = 1.78, 95%CI=1.23, 2.58), glycochenodeoxycholic acid (OR = 1.68, 95%CI=1.13, 2.48), taurochenodeoxycholic acid (OR = 1.62, 95%CI=1.11-2.36), and glycohyocholic acid (OR = 1.65, 95%CI=1.13, 2.40) as well as the secondary bile acids glycodeoxycholic acid (OR = 1.68, 95%CI=1.12, 2.54) and taurodeoxycholic acid (OR = 1.54, 95%CI=1.02, 2.31). By contrast, unconjugated bile acids and tertiary bile acids were not associated with risk.This prospective study showed that pre-diagnostic levels of certain conjugated primary and secondary bile acids were positively associated with risk of colon cancer. Our findings support experimental data to suggest that a high bile acid load is colon cancer promotive.
000144635 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000144635 588__ $$aDataset connected to CrossRef, PubMed,
000144635 7001_ $$aStepien, Magdalena$$b1
000144635 7001_ $$aLópez-Nogueroles, Marina$$b2
000144635 7001_ $$0P:(DE-HGF)0$$aMachado, Antje Damms$$b3
000144635 7001_ $$0P:(DE-He78)fd4ffe2a3f08e0158b82400acd6716be$$aSookthai, Disorn$$b4$$udkfz
000144635 7001_ $$0P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aJohnson, Theron$$b5$$udkfz
000144635 7001_ $$aRoca, Marta$$b6
000144635 7001_ $$0P:(DE-He78)6519c85d61a3def7974665471b8a4f74$$aHüsing, Anika$$b7$$udkfz
000144635 7001_ $$aMaldonado, Sandra González$$b8
000144635 7001_ $$aCross, Amanda J$$b9
000144635 7001_ $$aMurphy, Neil$$b10
000144635 7001_ $$aFreisling, Heinz$$b11
000144635 7001_ $$aRinaldi, Sabina$$b12
000144635 7001_ $$aScalbert, Augustin$$b13
000144635 7001_ $$aFedirco, Veronika$$b14
000144635 7001_ $$aSeveri, Gianluca$$b15
000144635 7001_ $$aBoutron-Ruault, Marie-Christine$$b16
000144635 7001_ $$aMancini, Francesca Romana$$b17
000144635 7001_ $$0P:(DE-HGF)0$$aSowah, Solomon A$$b18
000144635 7001_ $$aBoeing, Heiner$$b19
000144635 7001_ $$aJakszyn, Paula$$b20
000144635 7001_ $$aSánchez, Maria-Jose$$b21
000144635 7001_ $$aMerino, Susana$$b22
000144635 7001_ $$aColorado-Yohar, Sandra$$b23
000144635 7001_ $$aBarricarte, Aurelio$$b24
000144635 7001_ $$aKhaw, Kay Tee$$b25
000144635 7001_ $$aSchmidt, Julie A$$b26
000144635 7001_ $$aPerez-Cornago, Aurora$$b27
000144635 7001_ $$aTrichopoulou, Antonia$$b28
000144635 7001_ $$aKarakatsani, Anna$$b29
000144635 7001_ $$aThriskos, Paschalis$$b30
000144635 7001_ $$aPalli, Domenico$$b31
000144635 7001_ $$aAgnoli, Claudia$$b32
000144635 7001_ $$aTumino, Rosario$$b33
000144635 7001_ $$aSacerdote, Carlotta$$b34
000144635 7001_ $$aPanico, Salvatore$$b35
000144635 7001_ $$aBueno-de-Mesquita, Bas$$b36
000144635 7001_ $$avan Gils, Carla H$$b37
000144635 7001_ $$aHeath, Alicia$$b38
000144635 7001_ $$aGunter, Marc J$$b39
000144635 7001_ $$aRiboli, Elio$$b40
000144635 7001_ $$aLahoz, Agustín$$b41
000144635 7001_ $$aJenab, Mazda$$b42
000144635 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b43$$eLast author$$udkfz
000144635 773__ $$0PERI:(DE-600)1465951-7$$a10.1093/jnci/djz166$$gp. djz166$$n5$$p516-524$$tJournal of the National Cancer Institute$$v112$$x1460-2105$$y2020
000144635 909CO $$ooai:inrepo02.dkfz.de:144635$$pVDB
000144635 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000144635 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000144635 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd4ffe2a3f08e0158b82400acd6716be$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000144635 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000144635 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6519c85d61a3def7974665471b8a4f74$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000144635 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000144635 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b43$$kDKFZ
000144635 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000144635 9141_ $$y2020
000144635 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000144635 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJNCI-J NATL CANCER I : 2017
000144635 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144635 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144635 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144635 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000144635 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000144635 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000144635 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144635 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000144635 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144635 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144635 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000144635 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000144635 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000144635 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJNCI-J NATL CANCER I : 2017
000144635 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000144635 9200_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000144635 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000144635 980__ $$ajournal
000144635 980__ $$aVDB
000144635 980__ $$aI:(DE-He78)C020-20160331
000144635 980__ $$aUNRESTRICTED